Marekani - Kiingereza - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa 25 mg - carbidopa and levodopa tablets are indicated in the treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. this product is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin b6 ). in some patients a somewhat smoother antiparkinsonian effect results from therapy with carbidopa and levodopa than with levodopa. however, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from carbidopa and levodopa. although the administration of carbidopa permits control of parkinsonism and parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial othe

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; hyprolose; trehalose dihydrate; magnesium stearate; carmellose sodium; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg) - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; magnesium stearate; carmellose sodium; microcrystalline cellulose; trehalose dihydrate; hyprolose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: sodium sulfate; hyprolose; carmellose sodium; microcrystalline cellulose; magnesium stearate; trehalose dihydrate; powdered cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: powdered cellulose; microcrystalline cellulose; sodium sulfate; carmellose sodium; magnesium stearate; hyprolose; trehalose dihydrate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - carbidopa monohydrate 27mg equivalent to carbidopa 25mg; levodopa 100mg - tablet - active: carbidopa monohydrate 27mg equivalent to carbidopa 25mg levodopa 100mg excipient: crospovidone magnesium stearate microcrystalline cellulose pregelatinised maize starch quinoline yellow - levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/ carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea, and postural instability associated with parkinson's disease and syndrome. when therapeutic response to levodopa alone is irregular, and signs and symptoms of parkinson's disease are not evenly controlled throughout the day, substitution of levodopa/carbidopa usually is effective in reducing fluctuations in response. by reducing certain adverse reactions produced by levodopa alone, levodopa/carbidopa permits more patients to obtain adequate relief of the symptoms of parkinson's disease. levodopa/carbidopa is also indicated for patients with parkinsonism who are taking vitamin preparations that contain pyridoxine hydrochloride (vitamin b6).

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - carbidopa monohydrate 27mg equivalent to carbidopa 25mg; levodopa 250mg - tablet - active: carbidopa monohydrate 27mg equivalent to carbidopa 25mg levodopa 250mg excipient: crospovidone indigo carmine magnesium stearate microcrystalline cellulose pregelatinised maize starch - levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/ carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea, and postural instability associated with parkinson's disease and syndrome. when therapeutic response to levodopa alone is irregular, and signs and symptoms of parkinson's disease are not evenly controlled throughout the day, substitution of levodopa/carbidopa usually is effective in reducing fluctuations in response. by reducing certain adverse reactions produced by levodopa alone, levodopa/carbidopa permits more patients to obtain adequate relief of the symptoms of parkinson's disease. levodopa/carbidopa is also indicated for patients with parkinsonism who are taking vitamin preparations that contain pyridoxine hydrochloride (vitamin b6).

Marekani - Kiingereza - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - carbidopa anhydrous 12.5 mg - carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-o-methyltransferase-comt inhibitor) is indicated for the treatment of parkinson’s disease. carbidopa, levodopa and entacapone tablets can be used: carbidopa, levodopa and entacapone tablets are contraindicated in patients: there are no adequate and well-controlled studies in pregnant women. it has been reported from individual cases that levodopa crosses the human placental barrier, enters the fetus, and is metabolized. in animals, administration of carbidopa-levodopa or entacapone during pregnancy was associated with developmental toxicity, including increased incidences of fetal malformations. carbidopa, levodopa and entacapone tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in nonclinical studies in which carbidopa-levodopa was administered to pregnant animals, increased incidences of viscer

Marekani - Kiingereza - NLM (National Library of Medicine)

sandoz inc - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - carbidopa anhydrous 50 mg - carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-o-methyltransferase-comt inhibitor) are indicated for the treatment of parkinson's disease. carbidopa, levodopa and entacapone tablets can be used: carbidopa, levodopa and entacapone tablets are contraindicated in patients: pregnancy category c there are no adequate and well-controlled studies in pregnant women. it has been reported from individual cases that levodopa crosses the human placental barrier, enters the fetus, and is metabolized. in animals, administration of carbidopa-levodopa or entacapone during pregnancy was associated with developmental toxicity, including increased incidences of fetal malformations. carbidopa, levodopa and entacapone tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in nonclinical studies in which carbidopa-levodopa was administered to pregnant animals, increase

Marekani - Kiingereza - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - carbidopa anhydrous 12.5 mg - carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-o-methyltransferase-comt inhibitor) is indicated for the treatment of parkinson’s disease. carbidopa, levodopa and entacapone tablets can be used: - to substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. - to replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. carbidopa, levodopa and entacapone tablets are contraindicated in patients: - taking nonselective monoamine oxidase (mao) inhibitors (e.g., phenelzine and tranylcypromine). these nonselective mao inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa, levodo